Cyngn Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Cyngn Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $219.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $368.1K | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.49M | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | $262.0K | Mar 7, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.47M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($33.34M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($22.81M) | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | ($19.24M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($7.80M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($8.34M) | Mar 24, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.69M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($22.83M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($23.35M) | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | ($19.40M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($9.40M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($8.37M) | Mar 24, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.47M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $11.26M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $12.72M | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | $9.48M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $4.99M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $5.12M | Mar 24, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($23.58M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($19.20M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($19.48M) | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | ($16.30M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($8.64M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($7.92M) | Mar 24, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.23M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.05M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.05M | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | $918.3K | Mar 7, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.05M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $30.10M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $13.03M | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | $25.51M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $22.65M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $6.67M | Mar 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.30M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $31.14M | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | $2.40M | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | $1.39M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $407.4K | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.08M | Mar 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.75M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($1.05M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2023 | $10.64M | Mar 27, 2026 |
| FY2024 | Dec 31, 2022 | $24.12M | Nov 14, 2025 |
| FY2023 | Dec 31, 2021 | $22.25M | Mar 7, 2024 |
| FY2022 | Dec 31, 2020 | $5.60M | Mar 17, 2023 |
| FY2021 | Dec 31, 2019 | $13.80M | Mar 24, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($216.82M) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | ($193.35M) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | ($160.02M) | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | ($135.73M) | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | ($116.49M) | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | ($108.69M) | Mar 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $990.0K | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | $23.62M | Mar 27, 2026 |
| FY2023 | Dec 31, 2023 | $3.59M | Mar 7, 2024 |
| FY2023 | Dec 31, 2022 | $10.54M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | $21.95M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | $6.06M | Mar 24, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (2,521) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (6,528) | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 17, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (5) | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | (2,521) | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | (6,528) | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 17, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7.97M | Mar 27, 2026 |
| FY2025 | Dec 31, 2024 | 199,110 | Mar 27, 2026 |
| FY2024 | Dec 31, 2023 | 5,147 | Nov 14, 2025 |
| FY2023 | Dec 31, 2022 | 33.68M | Mar 7, 2024 |
| FY2022 | Dec 31, 2021 | 26.49M | Mar 17, 2023 |
| FY2021 | Dec 31, 2020 | 951,794 | Mar 24, 2022 |